The
global mycoplasma testing market size is
expected to grow by USD 445.57 million as per Technavio. This marks a
significant market growth compared to the 2019 growth estimates due to the
impact of the COVID-19 pandemic in the first half of 2020. Moreover, steady
growth is expected to continue throughout the forecast period, and the market
is expected to grow at a CAGR of over 11%.
Request for Technavio's latest
reports on directly and indirectly impacted markets
Market estimates include pre- and post-COVID-19 impact on the mycoplasma testing market -
Market estimates include pre- and post-COVID-19 impact on the mycoplasma testing market -
The global outbreak of COVID-19 has compelled several companies in the
healthcare industry to focus on finding a cure for this life-threatening
disease. The number of pharmaceutical and biotechnology companies that focus on
biomedical research is increasing, resulting in rising demand for mycoplasma
testing to identify and eliminate mycoplasma contamination during the
development of cell-derived biological and pharmaceutical products. However,
the global outbreak of coronavirus is expected to have a neutral impact on the
growth of the mycoplasma testing market during the forecast period.
The market is driven by the increasing focus on R&D of
biopharmaceuticals. In addition, the growing M&A and partnerships between
CROs, and pharmaceutical and biotechnology companies is anticipated to boost
the growth of the mycoplasma testing market.
New class therapeutics such as cell therapy and gene therapy are gaining
popularity as a novel treatment for many chronic and acute diseases. Thus, many
pharmaceutical companies and research institutes are concentrating on the
R&D of these products owing to their huge market potential. However, cell
therapy products witness challenges around sterilization and its storage, as a
result of which, it has to be immediately administered to the patients. Common
mycoplasma species such as Acholeplasma laidlawii, Mycoplasma arginini,
Mycoplasma bovis, Mycoplasma fermentans, and Mycoplasma salivarium have been
identified as contamination in cell cultures and the biopharmaceutical
processes. A product developed with mycoplasma contamination triggers serious
side effects in humans. This is driving the demand for mycoplasma test kits.
Rapid mycoplasma test kits are commercially available in the market that can be
used in research labs and biopharmaceutical manufacturing companies for cell
line qualification and in-process monitoring.
Buy 1 Technavio report and get the
second for 50% off. Buy 2 Technavio reports and get the third for free.
Major Five Mycoplasma Testing Companies:
Agilent Technologies Inc.
Agilent Technologies Inc. has business operations under various
segments, such as life sciences and applied markets, diagnostics and genomics,
and Agilent CrossLab. The company's key offerings include MycoSensor PCR Assay
Kit, 50 Rxn, which is a gel-based PCR assay that can rapidly detect mycoplasma
infections in the human cell lines in less than four hours.
ATCC
ATCC operates its business through various segments, such as classic
media, specialty media, stem cell research, human cytogenetics, mycoplasma
detection, and molecular biology. The company's key products include Universal
Mycoplasma Detection Kit, which offers a quick and sensitive PCR-based test to
detect mycoplasma contaminants in cell culture.
Becton, Dickinson and Co.
Becton, Dickinson and Co. has business operations under various
segments, such as BD Medical, BD Life Sciences, and BD Interventional. The
company's key offerings include BD MAX System, which is a fully-integrated,
automated platform that performs nucleic acid extraction and real-time PCR
providing results for up to 24 samples across multiple syndromes in less than
three hours.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. operates its business through two segments:
pharmaceuticals and diagnostics. The company's key offerings include MycoTOOL
PCR Mycoplasma Detection Kit, which tests the absence of mycoplasma in cell
culture samples. It supplies all reagents for the amplification step. It is an
in-vitro amplification test optimized for detection of mycoplasma in cell
culture.
InvivoGen
InvivoGen has business operations under various segments, such as
research fields, biological tools, and custom services. The company offers
PlasmoTest, which is the first assay to utilize cells to signal the presence of
mycoplasma. It is a simple, rapid, and reliable assay for the visual detection
of mycoplasma contamination in cell cultures.
No comments:
Post a Comment